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Key Points
Higher ibrutinib DI is associated with improved PFS, independent of del17p or TP53 mutation.
Ibrutinib hold for >1 week, often needed to manage adverse events, is associated with increased PFS events.

Abstract
Ibrutinib, an oral inhibitor of Bruton’s tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK activesite occupancy in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was
maintained at 24 hours. It is unknown if intermittent interruption of ibrutinib therapy contributes to altered clinical
outcomes. We therefore evaluated the effect of ibrutinib dose adherence on patient outcomes in the phase 3
RESONATE trial. The overall mean dose intensity (DI) was 95% with median treatment duration of ∼9 months.
Pharmacokinetic assessment of ibrutinib exposure at 420-mg dose suggested similar exposure regardless of patient
weight or age. As assessed by independent review committee, patients with higher DI experienced longer median

progression-free survival (PFS) compared with those with lower DI regardless of del17p and/or TP53 status. Of 79
patients requiring a drug hold, treatment was restarted at the original dose in 73 (92%) patients. Mean duration of a
missed-dose event was 18.7 days (range, 8-56). Patients missing ≥8 consecutive days of ibrutinib had a shorter
median PFS vs those missing <8 days (10.9 months vs not reached). These results support sustained adherence to
once-daily ibrutinib dosing at 420 mg as clinically feasible to achieve optimal outcomes in patients with previously
treated CLL. The trial was registered at www.clinicaltrials.gov as #NCT01578707.

Introduction
Intermittent chemotherapy or chemoimmunotherapy has been the standard therapeutic approach for chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).1-4 Ibrutinib, an oral Bruton’s tyrosine kinase
(BTK) inhibitor, demonstrated improved progression-free survival (PFS), overall survival (OS), and overall response
rate (ORR) compared with ofatumumab in a randomized phase 3 trial (RESONATE) of relapsed CLL/SLL.5
Using once-daily ibrutinib 420 mg in patients with CLL/SLL, BTK active-site occupancy was achieved at 4 hours
and maintained at 24 hours.6 Transient reversal of treatment-related lymphocytosis and regrowth of lymph nodes
occurred with intermittent dosing,6 suggesting rapid reversal of the biological effect. Additionally, fewer patients
(26% to 51%) maintained optimal BTK occupancy (>95%) at lower daily ibrutinib doses (140-280 mg).7 The
implications of interrupted therapy with ibrutinib are not known.
Sustained adherence to oral tyrosine kinase inhibitors is indicated as an important factor in achieving efficacy.8,9
Although once-daily dosing at 420 mg and lack of treatment interruptions could be needed for maximal benefit of
ibrutinib, this has not been adequately addressed. Given that dose interruption/modification is warranted for
treatment-related toxicity and invasive procedures, as recommended with ibrutinib use,10,11 we examined clinical
impact of prolonged dose delays and reductions of ibrutinib in the RESONATE study.

Patients and methods
Design and interim analysis of RESONATE have been previously published.5
Treatment adherence to ibrutinib was measured by overall dose intensity (DIoverall) and DI in the first 8 weeks (DI8week). DI was defined as the proportion of administered vs planned doses (for details on choice of 8-week interval
and dosing, see supplemental Methods, available on the Blood Web site). The independent review committee (IRC)–
assessed PFS and ORR in this retrospective analysis provide independent assessment of the impact of DI on
outcomes.
The study was approved by the institutional review board or independent ethics committee at each institution.

Results
DI
All patients (N = 195) started on oral ibrutinib 420 mg once-daily, regardless of age, weight, or baseline
comorbidities, and experienced similar exposure regardless of weight or age (supplemental Figure 1). The mean
DIoverall was 95%, and the mean DI8-week was 96%, with a median treatment duration of ∼9 months. Although not
statistically significant, patients with DI8-week below the mean (low DI) were older, had more advanced disease, and
had more prior therapies compared with patients with DI8-week above the mean (high DI). Other baseline
characteristics were similar between the 2 groups (supplemental Table 1).
Seventy-nine patients had dose holds for adverse events (AEs), 73 (92%) of whom restarted therapy at 420 mg
consistent with United States Prescribing Information and European Union labels10,11; 5 patients restarted at a lower
dose, and 1 did not restart therapy prior to data cutoff.
Eight patients had dose reductions because of AEs; 7 (3.6%) required a dose reduction to 280 mg, and 1 (0.5%)
required a dose reduction to 140 mg. Four of 8 dose-reduced patients restarted or reattained the 420-mg dose.
Diarrhea was the only AE resulting in dose reduction in >1 patient.
DI and survival outcomes

Fewer PFS events occurred in patients with high DI8-week vs those with low DI8-week (15% vs 26%), and similar
results were observed for DIoverall (12% vs 33%, respectively). PFS was significantly longer in patients with high
DI8-week vs low DI8-week (median PFS, NR [not reached] vs 6.9 months, P = .0127) (Figure 1A). Patients with
del17p or TP53 mutation with high DI8-week also experienced fewer PFS events vs those with low DI8-week, with a
significant difference in PFS (Figure 1B; P = .0444). Given the higher number of patients with low creatinine
clearance and advanced-stage disease in the low DI8-week group (supplemental Table 1), a subgroup analysis was
performed that showed no impact of these factors on PFS (supplemental Figure 2). An exploratory PFS analysis of
DIoverall using a clinically relevant 80% cutoff revealed a marked difference in PFS for patients with DIoverall ≥80%
vs those with DIoverall <80% (median NR vs 6.3 months, P < .0001; supplemental Figure 3).
Further, fewer deaths occurred in the high DI8-week vs low DI8-week group (5.8% vs 13.2%), with a trend toward
improved OS (Figure 1C; P = .0938). The 6- and 12-month OS rates were 95% and 94% with high DI8-week vs 90%
and 75% with low DI8-week.
Consecutive missed doses during entire treatment duration and survival outcomes per IRC
Fifty-eight patients who missed ≥8 consecutive days of ibrutinib 420 mg (supplemental Figure 4) had 78 missed-dose
events, of which 54 events (69%) occurred primarily because of AEs, 10 (13%) because of surgeries, and 3 (0.4%)
because of biopsies (supplemental Table 2). Mean duration of a missed-dose event in all treated patients was 18.7
days (range, 8-56). Patients with missed doses for ≥8 days experienced more IRC-assessed PFS events (17/57 [30%])
compared with patients missing <8 days (17/137 [12%]) with a significant difference in median PFS (10.9 months vs
NR; P = .0151) (supplemental Figure 5).
IRC-assessed ORR
The ORR was 67% in patients with high DI vs 43% in those with low DI (P = .0080). Approximately 95% of patients
with high DI experienced >50% reduction in the sum of the product of greatest diameters vs 82% of patients with low
DI (Figure 2).
Post-IRC progression outcomes
With an additional 16-month follow-up (total median follow-up, 30.4 months; range, 0.33-36.5), 22/26 (84%) patients
with IRC-confirmed progressive disease (PD) discontinued therapy. Fifteen of 26 (58%) patients who progressed by
IRC also progressed clinically by investigator assessment prior to discontinuing ibrutinib. Ten of 26 patients who
progressed by investigator assessment discontinued within 2 months of the independent PD event. Four of 26 patients
with IRC-confirmed PD continue on ibrutinib at the time of analysis (supplemental Table 3).

Discussion
These retrospective analyses suggest that optimal adherence to the recommended ibrutinib dosage is associated with
superior patient outcomes. Patients with higher mean DI demonstrated improved independently assessed PFS, higher
ORR, and a trend toward improved OS. Ibrutinib hold for >1 week (∼3% reduction in DI) during the entire treatment
duration was associated with increased PFS events. Because of the small number of dose-reduced patients (n =
8/195), it is difficult to draw an inference on the outcomes based on dose reduction.
Although IRC-confirmed PD represents independently confirmed disease, some of these events appear to be transient
in nature following dose holds, with 11/26 (42%) patients being able to continue therapy without clinical progression
for a period of time (>6.5 months). As such, following a dose hold, even with some increase in disease burden (lymph
nodes or spleen), ibrutinib can provide continued disease control. It should be noted that dose interruptions/holds are
clinically appropriate and inevitable in certain cases (eg, AE management, perioperative holds); however, our
findings emphasize the importance of restarting and continuing the 420-mg dose, as soon as clinically appropriate, for
optimal benefit. Additionally, therapy should not be discontinued without good cause, because the model for ibrutinib
therapy is continuous treatment. Our data are supported by a recent report demonstrating that patients on ibrutinib
who had treatment breaks >14 days during the first year experienced poor survival outcomes at ≥1 year.12

Further, ibrutinib should be initiated at 420 mg daily in all patients with CLL/SLL irrespective of weight or age, with
similar exposure levels in these patients supporting this recommendation. Moreover, it may be important to avoid
subtherapeutic drug levels, as this may promote resistance as observed in other tyrosine kinase inhibitor settings.13-15
Altogether, these data support the 420-mg dose and continuous administration schedule of ibrutinib in CLL/SLL that
formed the basis of the superior efficacy observed in randomized studies.
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Figure 1.
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Survival outcomes by mean DI. (A) PFS in all patients by 8-week mean DI. (B) PFS in patients with del17p or TP53 mutation by 8week mean DI. (C) OS in all patients by 8-week mean DI.

Figure 2.
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Maximum percent improvement from baseline in sum of the product of greatest diameters (SPD) based on mean DI between
first dose and first disease assessment. Ninety-five percent of patients with high DI (above the mean) experienced a >50% reduction
in SPD vs 82% of patients with low DI (below the mean).
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